Patent Application
20240075184
Temporary surgical implants, especially those made from magnesium alloys, are known for their biodegradation and biocompatibility, allowing for an implant that does not require secondary surgery for removal. However, magnesium alloy implants corrode rapidly under physiological conditions, often before bone healing can occur, leading to implant failure.
Embodiments of the present disclosure provide biodegradable orthopedic implants, corrosion-resistant coating for orthopedic implants, methods of making coated orthopedic implants, and the like.
An embodiment of the present disclosure includes a biodegradable orthopedic implant. The implant can include a Mg alloy and have a coating including PCL and lawsone.
An embodiment of the present disclosure also includes a corrosion-resistant coating for orthopedic implants, the coating including a first layer, a second layer, and a third layer. The first layer can be an oxide layer coated on an external surface of a magnesium alloy implant. The second layer can include lawsone embedded in PCL, and the third layer can include a polymer.
An embodiment of the present disclosure also includes method of making a coated orthopedic implant. The method can include immersing a magnesium alloy implant in an alkaline solution to form an oxide-coated implant and coating the oxide-coated implant with a PCL-lawsone solution to form a coated orthopedic implant.
Other compositions, apparatus, methods, features, and advantages will be or become apparent to one with skill in the art upon examination of the following drawings and detailed description. It is intended that all such additional compositions, apparatus, methods, features and advantages be included within this description, be within the scope of the present disclosure, and be protected by the accompanying claims.
Further aspects of the present disclosure will be more readily appreciated upon review of the detailed description of its various embodiments, described below, when taken in conjunction with the accompanying drawings.
The drawings illustrate only example embodiments and are therefore not to be considered limiting of the scope described herein, as other equally effective embodiments are within the scope and spirit of this disclosure. The elements and features shown in the drawings are not necessarily drawn to scale, emphasis instead being placed upon clearly illustrating the principles of the embodiments. Additionally, certain dimensions may be exaggerated to help visually convey certain principles. In the drawings, similar reference numerals between figures designate like or corresponding, but not necessarily the same, elements.
Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described.
As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.
Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of chemistry, material science, and the like, which are within the skill of the art.
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to perform the methods and use the materials disclosed and claimed herein. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C., and pressure is at or near atmospheric. Standard temperature and pressure are defined as 20° C. and 1 atmosphere.
Before the embodiments of the present disclosure are described in detail, it is to be understood that, unless otherwise indicated, the present disclosure is not limited to particular materials, reagents, reaction materials, manufacturing processes, or the like, as such can vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting. It is also possible in the present disclosure that steps can be executed in different sequence where this is logically possible.
It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
Lawsone, as used herein, refers to (2-hydroxy-1,4-napthoquinone), which is a natural red-orange dye extracted from the leaves of Lawsonia inermis plant, commonly known as “henna”.
Polycaprolactone (PCL), as used herein, refers to a synthetic polymer that is a biodegradable polyester with a low melting point of around 60° C. and a glass transition temperature of about −60° C. Polycaprolactone is alternatively known as poly ε-caprolactone.
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in some aspects, relate to Magnesium alloy orthopedic implants including anticorrosive coatings.
In general, embodiments of the present disclosure provide for methods of making the anticorrosive coatings, coating compositions including PCL and lawsone, and biodegradable implants including the coating compositions.
The present disclosure includes biodegradable orthopedic implants having a coating that can include polycaprolactone (PCL) and lawsone. The implant can contain a magnesium alloy and can biodegrade over time as the surrounding bone heals. Advantageously, the coating can impart anti-corrosive properties to the implant, allowing the implant to biodegrade more slowly. The coating can have antibacterial properties and is noncytotoxic.
In some embodiments, the coating provided herein can have multiple layers. In some embodiments, the coating can have a first layer, a second layer, and a third layer. The first layer can be an oxide layer on an external surface of the implant. The second layer can be an inhibition layer including a corrosion inhibitor and a polymer. In an embodiment, the inhibition layer can include lawsone embedded in PCL. The third layer can be a polymer protective layer. In some embodiments the polymer protective layer can be or can include PCL. In some embodiments, the PCL can be substituted with or used in conjunction with other natural or synthetic polymers with suitable biocompatibility.
The first layer can be a dense oxide layer. After alkaline treatment, the dense oxide layer is formed on the surface of a Mg alloy to protect the highly susceptible Mg alloy surface against corrosion during the coating procedure. In some embodiments, the oxide layer can be about 4 μm. The dense oxide layer can be formed by immersion of the implant in an alkaline solution. In some embodiments, the alkaline solution is NaOH. The NaOH can have a concentration of about 0.1-5 M, and the immersion time can be about 1-24 hours, depending on the concentration.
A second layer including PCL and lawsone forms the middle layer. Lawsone is initially entrapped within the second layer of the coating as the corrosion inhibitor. A third, top PCL layer can be coated on the second as a barrier layer to minimize the leaching of the inhibitor. Advantageously, once a defect appears within the PCL coating, the lawsone molecule is released from the inner layer into the damaged area. The anticorrosive properties of lawsone are due to its ability to chelate Mg2+ metal cations from the Mg alloy to form a protective barrier. While the functional PCL-lawsone layer is adjacent to the Mg substrate, in some embodiments additional layers of PCL can be added on top of the functional layer to increase the passive barrier properties of the coating.
In some embodiments, the PCL and PCL-lawsone layers can be about 5 μm each. In some embodiments, the layer or layers comprising PCL and lawsone can include about 0.1% w/w to 3% w/w, about 0.5% w/w to 1.5% w/w, or about 1% w/w of lawsone to PCL. In a particular embodiment, a ratio of about 1% w/w lawsone to PCL can provide both antibacterial and anticorrosion properties. However, a lower concentration of lawsone can also be used as a corrosion inhibitor but would not show notable antibacterial properties.
In some embodiments, the corrosion inhibitor (e.g. lawsone) is directly added into the coating (e.g. PCL). In other embodiments, the lawsone and/or other corrosion inhibitors can be encapsulated in micro/nanoparticles and then incorporated into the polymeric coating to minimize the undesired leaching or obtain stimuli-responsive release of the inhibitor. Lawsone can be encapsulated in various micro/nanoparticles including organic (polymeric particles such as carboxymethylcellulose, chitosan, PCL, polyurethane, polyelectrolyte nanocapsules, polystyrene containers, etc.) and inorganic (such as halloysites, mesoporous silica, mesoporous TiO2, layered double hydroxides, hydroxyapatite, etc.) nanocontainers. The encapsulation can provide protection of the inhibitor by preventing uncontrollable release or undesired chemical reactions with the coating material and has been shown to increase the corrosion protection of the substrate when compared to directly adding the inhibitor into the coating material. The inhibitor chemical agent remains sequestered and protected within the capsule until released by damage to the coating.
The implant can be biodegradable implant, such as a Mg—Al—Zn alloy. In some embodiments, the Mg—Al—Zn alloy can have an Al content of about 3% to 13%, about 2.75% to 5%, or about 3%. In a particular embodiment, the Mg—Al—Zn alloy can be AZ31.
Described herein is an anti-corrosive polymeric coating as above, which includes a synthetic polymer and lawsone. The coating can be included on temporary orthopedic implants, such as implants comprising magnesium alloys.
Embodiments of the present disclosure also provide for methods of making coated orthopedic implants as above. The method can include immersing a magnesium alloy implant in an alkaline solution to form an oxide-coated implant and coating the oxide-coated implant with a PCL-lawsone solution. A layer including PCL can be coated on the top.
Advantageously, the coating described herein can prevent, delay and/or mitigate formation of hydrogen-forming gas pockets around the implant.
The implants described herein can be such as a screw, a plate, a nail, a pin, a rod, or a prosthesis, as can be envisioned by one of ordinary skill in the art.
Now having described the embodiments of the disclosure, in general, the examples describe some additional embodiments. While embodiments of the present disclosure are described in connection with the example and the corresponding text and figures, there is no intent to limit embodiments of the disclosure to these descriptions. On the contrary, the intent is to cover all alternatives, modifications, and equivalents included within the spirit and scope of embodiments of the present disclosure.
Magnesium (Mg) alloys have emerged as a new class of biodegradable metallic biomaterials in recent years. Especially, they have gained extensive attention as potential temporary orthopedic bone implants such as fixation screws, plates and pins for the healing of bone defects owing to their biocompatibility and biodegradability, and mechanical properties suitable to natural human bones. In the physiological environment, Mg alloy can be degraded and safely adsorbed by the human body with no inflammatory responses, while the damaged bone tissue is being reconstructed and substituted with them. This eliminates the need for a second surgery to remove the implant from the body after full healing of the bone defect.
Despite all the desirable properties of Mg alloys, their practical application is still limited because of their poor corrosion resistance and rapid degradation rate [5]. Fast corrosion results in excess H2 generation at the implant site, local alkalization, and deteriorated mechanical integrity of the implant which may delay the healing process and even cause tissue necrosis [6-8]. Together, these issues emphasize the need for novel strategies to tailor the corrosion/degradation rate of Mg alloys and expand their clinical application as bioimplants.
Numerous corrosion protection methods including surface chemical treatment [9], phosphate coating [10], anodization [11], micro-arc oxidation [12], and polymeric coating [13] have been adopted for Mg alloys so far. Among them, polymeric coatings have been recognized as the most effective method to tailor the corrosion rate of Mg alloys without changing their bulk properties [14]. Besides, they can provide other functionalities to the substrate such as enhanced biocompatibility and cellular responses, ability to load small molecules, self-healing, and antibacterial properties [13].
Several synthetic polymers such as polylactic acid (PLA) [15], poly(lactic-co-glycolic) acid (PLGA) [16], polydopamine [17], and polycaprolactone (PCL) [18] as well as natural polymers like chitosan [19] and silk fibroin [7] have been used as protective coatings on Mg alloys in biomedical applications. Although these polymeric coatings can improve the corrosion resistance of Mg alloys to a certain degree, they are susceptible to damage by the highly corrosive environment of the human body, which results in polymer degradation and deterioration of protective barrier properties [20]. Following the emergence of defects or micro-cracks within a coating, corrosive species and water penetrate through the defected areas of the coating and reach the Mg alloy surface, leading to the occurrence of localized corrosion (mainly pitting corrosion) and rapid degradation of Mg alloys [21].
Introducing corrosion inhibitors into the polymeric coatings have shown great potential to improve the anti-corrosion properties and durability of the polymeric coatings [22]. Generally, a composite polymer/corrosion inhibitor coating consists of a polymeric coating as a passive physical barrier, hosting an active corrosion inhibitor within the coating matrix. When the barrier coating is damaged by corrosive species, the loaded corrosion inhibitor can be released into the defected sites and mitigate the corrosion progression by forming insoluble metal complexes [23, 24]. Several inorganic and organic corrosion inhibitors such as cerium ion [25], 8-hydroxyquinoline [26], vanadate [27], molybdate [28], and benzotriazole [29] have been proposed for corrosion protection of Mg alloys so far. Although being effective in corrosion mitigation, most of these synthetic inhibitors are not suitable for implantable biomedical applications due to their potential cytotoxic and carcinogenic effects in the physiological environment [30, 31].
Eco-friendly corrosion inhibitors also known as “green” inhibitors have emerged as promising alternatives to hazardous synthetic inhibitors [32]. Among all the green alternatives, plant-derived corrosion inhibitors have gained considerable attraction, as they possess desired biocompatibility while being inexpensive and available through renewable resources [33, 34]. Lawsone (2-hydroxy-1,4-napthoquinone) is a natural red-orange dye, extracted from the leaves of Lawsonia inermis plant, commonly known as “Henna”. As the main active ingredient of Henna, lawsone has well-known corrosion inhibition properties based on the chelation of metal cations [35, 36]. It has been used as a corrosion inhibitor for different metal substrates such as steel and aluminum alloys in non-medical applications, by either adding it to a corrosion solution or incorporating it in a coating formulation [37, 38]. In a comprehensive study by Lamaka et al. [39], inhibition efficiencies of multiple corrosion inhibitors on Mg and its alloys were examined through hydrogen evolution test. Lawsone (0.4 M in corrosion solution) showed excellent inhibition efficiencies of 97% and 90% for high-purity Mg (Fe % 51 ppm) and Mg alloy AZ31, respectively.
In addition to the corrosion inhibition properties, lawsone is non-toxic to the human body and has been widely used in various biomedical applications such as wound healing [40], antibacterial coating [41], and cancer treatment [42]. Moreover, it has been reported that lawsone possesses antibacterial and antibiofilm activities against gram-positive and gram-negative bacteria [43]. Such antibacterial effects can be helpful in the prevention of microbial infection and failure of the implant especially at early stages after implantation [44]. Taken together, lawsone is an attractive candidate to be used in the fabrication of protective coatings on biodegradable Mg-based orthopedic implants. To date, lawsone has not been considered for use as an anticorrosive inside the human body.
Described herein is a composite coating on a Mg alloy for biodegradable bone implant application. The studies provided herein demonstrate the first time lawsone has been incorporated into a coating formulation to improve the corrosion resistance properties of an Mg-based alloy. The structure of the proposed composite coating on the AZ31 Mg substrate is schematically presented in
Chemicals and Reagents—Poly(ε-caprolactone) (PCL) with the average molecular weight of 80,000 g/mol and lawsone (2-Hydroxy-1,4-naphthoquinone, 97%) were purchased from Sigma-Aldrich. Dichloromethane was obtained from EMD chemicals. All other reagents, unless otherwise specified, are of reagent grade. Milli-Q water (resistivity=18 MΩ.cm) was used for the preparation of all electrolytes and aqueous solutions.
Preparation of AZ31 Substrates—AZ31 Mg alloy sheet with a thickness of 1 mm was cut into the pieces of 2×2 cm. AZ31 samples were first mechanically polished by 2000-grit silicon carbide abrasive paper to remove contamination and native oxides layer. Then, they were ultrasonically cleaned in ethanol and distilled water each for 5 min, and finally dried in an oven at 60° C. The chemical composition of the AZ31 alloy is shown in Table 1.
Alkaline Pretreatment—Before applying the polymeric coating on the Mg alloy surface, it is necessary to provide the Mg sample with primary protection against possible corrosion during the coating process. In this study, alkaline treatment was used to form a passive layer of Mg(OH)2 on the Mg surface to enhance its corrosion resistance. To do so, all Mg samples were immersed in 1 M NaOH solution at 80° C. for 4 h. After the reaction was completed, samples were thoroughly rinsed with deionized (DI) water and dried at 80° C. This sample was labeled as “AZ31-OH”.
Fabrication of PCL-Lawsone Coatings—PCL solution (1% w/v) was prepared by dissolving PCL in dichloromethane using a magnetic stirrer for 1 h. Lawsone powder was added to the PCL solution and stirred to obtain a homogenous solution with 1% w/w of lawsone with respect to PCL weight. The resulting PCL/lawsone solution (200 μL) was pipetted on alkaline pretreated Mg samples and dried under the hood for 24 h at room temperature. During the drying process, all samples were placed on glass Petri dishes with closed lids to control the solvent evaporation rate. The same process was repeated for the other side of the samples. To prepare the top coating, a pure PCL solution (200 μL) was pipetted on both sample sides. The lawsone-interbedded samples were labeled as “PCL-LS”. Meanwhile, specimens coated with pure PCL were also prepared as controls under the same condition and denoted as “PCL”.
Coating Characterization—The surface and cross-section morphologies of the coatings were visualized by a scanning electron microscope (SEM, FEI Teneo, FEI Co.). Before SEM observation, the samples were gold-sputtered to improve conductivity. The functional groups of the coatings were recognized by attenuated total reflectance-Fourier transform Infrared analysis (ATR-FTIR, Nicolet 6700, Thermo Electron Corporation, MA, USA). The spectra were recorded from 4000 to 800 cm−1 in wavenumber and 128 scans with a resolution of 4 cm−1. The surface hydrophilicity of samples was measured using a Krüss DSA 100 drop shape analyzer at room temperature. The static contact angle was measured by the dropwise addition of distilled water (1 μL) onto the sample surface.
In vitro Corrosion Evaluation: Electrochemical Measurements—Hank's solution (compositions are listed in Table 2) was used for electrochemical and immersion experiments (according to ASTM-G31-72) to mimic the main inorganic components of the
corrosive aqueous media in the human body [50]. Electrochemical measurements were conducted in a custom-made corrosion cell in Hank's solution using CHI-920c model potentiostat (CH Instruments Inc., Austin, TX). The set-up consists of three electrodes with Mg samples exposing a surface area of 1 cm2 as the working electrode, a silver/silver chloride (Ag/AgCl 3 M) reference electrode, and a platinum wire as the counter electrode. First, the open circuit potential (OCP) values of samples were recorded for 30 min without any external disturbance. Then, electrochemical impedance spectroscopy (EIS) measurement was carried out at OCP between frequencies of 10−2 to 105 Hz with an AC amplitude of ±10 mV. Immediately, after the EIS test, a potentiodynamic polarization (PP) test was performed from −250 mV to +250 mV vs OCP at a scan rate of 1 mV/s to evaluate the corrosion behavior of the coatings. The EIS data were quantitatively simulated using appropriate equivalent circuit (EC) models. EIS measurements of coated samples after 1, 3, and 7 days of immersion in Hank's solution were also carried out under the same conditions. All electrochemical corrosion experiments were carried out in triplicates, and the average values was used for analyses. The corrosion potential (Ecorr) and corrosion current density (Icorr) were determined from PP curves by Tafel extrapolation method. The inhibition efficiency (IE) of each sample was calculated using Eq. 1 as below [51]:
Where Io and Ii are the corrosion current densities of AZ31 (control sample) and the tested sample, respectively.
Immersion Experiments—Samples were immersed in a sealed vial containing Hank's solution at 37° C. with a volume-to-sample area ratio of 20 mL/cm2 (ASTM G31-72). For each sample, the volume of evolved hydrogen generated by Mg samples was measured every 24 h up to 7 days. The experimental set-up for this test consists of an inverted funnel-burette system above the sample, immersed in a solution-filled container. Meanwhile, the pH values of the immersion solutions were recorded during the immersion test. After immersion for 7 days, all samples were taken out and thoroughly rinsed with DI water to remove the corrosion products on the surface and quickly dried. Post-corrosion surface morphology was characterized using SEM and surface compositions were analyzed using ATR-FTIR analysis.
Antibacterial Activity Assay—Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) bacterial strains were used to study the antibacterial activities of the coatings using the Kirby-Bauer disk diffusion test [52]. Briefly, a pure bacterial culture is suspended in a phosphate buffer saline (pH 7.4), adjusted to a turbidity of 0.5 McFarland standard (equal to the density of a bacterial suspension with a 1.5×108 colony forming units (CFU/ml)), and swabbed uniformly across a culture plate. Mg samples were cut into pieces of 1×1 cm in diameter, sterilized under UV light for 1 h each side, and placed on the culture plates. After, incubating the plates at 37° C. for 24 h, the antibacterial activity was evaluated by measuring the diameter of the inhibitory zone formed around the samples.
Cytocompatibility: Cell culture—Fetal Osteoblast cells (hFOB 1.19-ATCC 11372) were cultured in 75 cm2 T-flasks with a 1:1 mixture of Ham's F12 Medium and Dulbecco's Modified Eagle's Medium, containing 0.3 mg/mL Geneticin (Gibco Life Technologies) and supplemented by 10% fetal bovine serum (FBS) in a humidified incubator at 37° C. with 5% CO2. The culture medium was replenished with fresh media every 2 days until cells were 90% confluent. Thereafter, the cells were detached from the T-flask surface by enzymatically degrading their extracellular matrix layer by treating them with 0.18% trypsin and 5 mM EDTA for 5 min.
Cell Viability—The effect of leach outs from the Mg samples in hFOB media were tested against Fetal Osteoblast cell proliferation. The sample leachates were obtained using cell culture media with an extraction media/surface area ratio of 1.25 mL/cm2 in a humidified atmosphere with 5% CO2 at 37° C. for 1,3, and 5 days according to ISO 10993-12 [53]. Around 5000 cells/mL were seeded in a cell culture grade 96-well plate and incubated for 24 h in a humidified incubator with 5% CO2 at 37° C. The manufacturer's protocol (Sigma-Aldrich) was followed to perform the cytocompatibility test using a CCK-8 kit on hFOB. After 24 h of cell culture incubation in a 96-well plate, 10 μL of the leachates (1.25 mL/cm2) from the samples were added (n=6) to the cells. The cells were allowed to respond to the leachates during a separate 24 h incubation period inside a cell culture incubator at physiological temperature. Then, 10 μL of the WST-8 solution was added to the resulting solution and incubated for 2 h. During this time, dehydrogenase enzymes from live cells acted on the WST-8 solution, converting it to an orange product, formazan, measurable at 450 nm. The relative viability (%) of the cells in response to sample leachates was reported relative to the control (without leachate exposure) using Eq. 2:
Statistical analysis—All data in this study were expressed as mean±standard deviation with n=3. One-way analysis of variance (ANOVA) tests was used to determine statistical significance, where significance was defined as p<0.5.
Coating Characterizations: Surface Morphology—
Chemical Composition of the Coatings—ATR-FTIR was employed to analyze the chemical compositions of the sample surfaces resulted from pretreatment and coatings. As shown in
Water Contact Angle—The hydrophilicity of the Mg samples was investigated by the water contact angle measurement test.
In vitro Corrosion Studies: Open Circuit Potential and Polarization Measurements—The electrochemical measurements were performed in Hank's solution to further investigate the corrosion resistance of each sample using OCP and PP (Tafel plot) measurements.
Potentiodymanic polarization curves can provide invaluable information about the corrosion process as well as the corrosion rate of the substrate being tested. The Tafel curves of AZ31, alkaline treated, and coated samples are shown in
EIS measurements—EIS was utilized as a powerful technique to further investigate the corrosion protection performance of the coatings and corrosion mechanism [63]. Nyquist plots and Bode plots (impedance and phase angle plots) of EIS spectra for the tested samples are presented in
EIS, as a non-destructive technique, can allow us to continuously monitor the corrosion resistance properties of a sample over a long period, as it does not perturb the system significantly due to its steady state measurement [72]. The effect of lawsone inhibitor on long-term protection performance of the coatings was studied through EIS measurements by comparing barrier properties of PCL and PCL-LS coatings during a 7-day immersion period in Hank's solution. Bode plots of PCL and PCL-LS coatings after 1,3, and 7 days of immersion and the corresponding fitted EIS parameters are presented in
Variation of log |Z|0.01 Hz for the PCL and PCL-LS over immersion time can be seen from Bode-impedance plots, which reflect the overall corrosion resistance of coatings. For the PCL coating (
According to Table 4, the Rct, Rout, and Rin values of PCL coatings all declined during the whole immersion time, reveling the successive deterioration of the physical barrier properties of the pure PCL coating over time [68]. In the case of PCL-LS coating, Rout increased from 2.48×106 to 6.84×106 Ω.cm2 after 24 h of immersion. Moreover, as the exposure time prolonged, n values related to CPEdl continuously rose, indicating that the Mg alloy surface is becoming smoother by time. That is most likely due to the formation of insoluble metal-lawsone complexes upon the release of lawsone and filling of the active corroding sites on the Mg substrate [75]. It should be also noted that, at the end of 7 day immersion time, the Rct value of PCL-LS coating is much higher than those of uncoated Mg samples and the pure PCL coating.
Immersion Corrosion Tests—
To further evaluate the long-term degradation of Mg samples, in vitro immersion studies were performed as a reliable measurement in addition to the typical electrochemical corrosion tests [76]. Corrosion of Mg alloys in aqueous electrolytes co-occurs with the generation of hydrogen gas and increment of pH value as per the below equation [77]:
Mg+2H2O→Mg2++2OH−+H2 (g)
The corrosion of each mole of Mg atom results in the generation of one mole of hydrogen gas and two moles of OH− anions. Therefore, monitoring the hydrogen evolution and pH value variation can provide precise information about the Mg corrosion as well as the protection efficiency of a coating on the Mg surface.
The trend of pH changes (
ATR-FTIR was used to investigate the compositions of corrosion products after immersion for 7 days in Hank's solution. As displayed in
Mechanism of Corrosion Inhibition of PCL-LS Coating—The corrosion inhibition property of the PCL-LS coating was verified by electrochemical corrosion studies as well as in vitro immersion tests. Lawsone is initially entrapped within the inner layer of the coating as the corrosion inhibitor, while a top PCL layer is coated on that as a barrier layer to minimize the leaching of the inhibitor. Once a defect appears within the PCL coating, the lawsone molecule is released from the inner layer into the damaged area. The anticorrosive properties of lawsone mainly rely on its ability to chelate metal cations—in our case Mg2+—to form a protective barrier on top of the underlying Mg substrate [38]. Exposing to a saline electrolyte like Hank's solution, the lawsone molecule undergoes a chemical rearrangement by delocalization of a pair of electrons on its hydroxyl group and then can form a complex with Mg2+ ions [81]. These insoluble complexes produced by lawsone molecules will be adsorbed onto the damaged area of the Mg surface and block the active sites of corrosion. The formed organic layer can seal and isolate the damaged substrate form the corrosive electrolyte and thus prevents further corrosion at the metal surface [36].
Antibacterial Studies—Antibacterial properties of the coatings were evaluated against E. coli and S. aureus, two bacterial strains mainly associated with the biomedical implant-related infections [44].
In vitro Cytocompatibility—To investigate the biosafety of coatings for bio-implant applications, the in vitro cytocompatibility of Mg samples were examined toward hFOB using CCK-8 test.
In this example, lawsone was used as a natural corrosion inhibitor and incorporated into the biocompatible PCL polymeric coating to improve the corrosion resistance of biodegradable AZ31 Mg alloy. The results of electrochemical corrosion tests and in vitro immersion studies clearly indicated that the corrosion protection performance of the PCL coating was significantly enhanced after incorporation of lawsone into the coatings. Also, the corrosion resistance of the AZ31 substrate was increased by almost two order of magnitudes (IE of 98.3%) after being coated with PCL-LS. Lawsone-containing coatings showed strong antibacterial activity against E. coli and S. aureus, which can be highly beneficial for bio-implant applications as it minimizes the risk of implant-related infection at the early stages. While most of commonly used Mg corrosion inhibitors have limited biomedical applications due to the concerns over their cytocompatibility, no cytotoxic effect was observed for PCL-LS coating toward hFOB cells. The results of this study suggested the proposed polymeric coating based on lawsone has great potential as a protective coating to expand the applicability of Mg alloys for biodegradable implant applications.
Additional tests were performed to characterize the PCL-lawsone (PCL-LS) coating on AZ31 Mg alloy.
Coating adhesion test: Adhesion strength of the PCL-LS protective coating to the AZ31 substrate was examined by the cross-cut tape test according to ASTM D3359. A lattice of 100 squares of 1 mm2 area each was formed on the coated samples using a sharp blade and a cross-cut guide. An adhesive tape (SEMicro CHT) was applied to the cross-cut area, rubbed with an eraser to ensure a firm contact between the tape and the test area, and quickly pulled off at an angle of 180° after 90 s. Depending on the percentage damage of the coatings, adhesion was graded according to ASTM standard chart, where 5B represents excellent adhesion (0% of coating detachment) and 0B represents very poor adhesion (>65% of coating detachment).
Having an adequate adhesion strength to the underlaying substrate is critical for any protective coatings as it determines the functionality and durability of the coating for the intended period of application. Interfacial adhesion between the Mg substrates and the PCL-LS coating was evaluated by the cross-cut adhesion test.
Cross-sectional SEM and EDS analyses: The surface and cross-section morphologies of the coatings were visualized by a scanning electron microscope (SEM, FEI Teneo, FEI Co.). The elemental analysis across the coating/substrate interface was obtained by an energy dispersive x-ray spectrometer (EDS) connected to the SEM.
The present disclosure will be better understood upon reading the following numbered aspects, which should not be confused with the claims. Any of the numbered aspects below can, in some instances, be combined with aspects described elsewhere in this disclosure and such combinations are intended to form part of the disclosure.
Aspect 1. A biodegradable orthopedic implant, comprising: an implant comprising a Mg alloy; and a coating comprising PCL and lawsone.
Aspect 2. The biodegradable orthopedic implant of aspect 1, wherein the coating comprises a first layer, a second layer, and a third layer; wherein the first layer is an oxide layer on an external surface of the implant; wherein the second layer comprises lawsone embedded in PCL; and wherein the third layer comprises a biocompatible polymer. In some aspects, the biocompatible polymer can comprise PCL.
Aspect 3. The biodegradable orthopedic implant of aspect 1 or 2, wherein the Mg alloy is a Mg—Al—Zn alloy.
Aspect 4. The biodegradable orthopedic implant of aspect 3, wherein the Mg—Al—Zn alloy has an Al content of about 3%.
Aspect 5. The biodegradable orthopedic implant of aspect 3, wherein the Mg—Al—Zn alloy is AZ31.
Aspect 6. The biodegradable orthopedic implant of any of aspects 2-5, wherein the second layer comprises about 0.1% to 1% w/w of lawsone to PCL.
Aspect 7. A corrosion-resistant coating for orthopedic implants, comprising: a first layer, a second layer, and a third layer; wherein the first layer is an oxide layer coated on an external surface of a magnesium alloy implant; wherein the second layer comprises lawsone embedded in PCL; and wherein the third layer comprises a biocompatible polymer. In some aspects, the biocompatible polymer can comprise PCL.
Aspect 8. The corrosion-resistant coating for orthopedic implants of aspect 7, wherein the second layer comprises about 0.1% to 1% w/w of lawsone to PCL.
Aspect 9. The corrosion-resistant coating for orthopedic implants of aspect 7 or 8, wherein the magnesium alloy implant comprises a Mg—Al—Zn alloy having an Al content of about 3%.
Aspect 10. A method of making a coated orthopedic implant, comprising immersing a magnesium alloy implant in an alkaline solution to form an oxide-coated implant; and coating the oxide-coated implant with a PCL-lawsone solution to form a coated orthopedic implant.
Aspect 11. The method of aspect 10, further comprising applying a protective polymer coating to the coated orthopedic implant. In some aspects, the protective polymer coating can comprise PCL.
Aspect 12. The method of aspect 10 or 11, wherein the alkaline solution is about 0.1-5 M NaOH.
Aspect 13. The method of any of aspects 10-12, wherein the PCL-lawsone solution comprises about 1% w/w of lawsone to PCL.
It should be noted that ratios, concentrations, amounts, and other numerical data may be expressed herein in a range format. It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. To illustrate, a concentration range of “about 0.1% to about 5%” should be interpreted to include not only the explicitly recited concentration of about 0.1 wt % to about 5 wt %, but also include individual concentrations (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5%, 1.1%, 2.2%, 3.3%, and 4.4%) within the indicated range. In an embodiment, “about 0” can refer to 0, 0.001, 0.01, or 0.1. In an embodiment, the term “about” can include traditional rounding according to significant figures of the numerical value. In addition, the phrase “about ‘x’ to ‘y’” includes “about ‘x’ to about ‘y’”.
It should be emphasized that the above-described embodiments of the present disclosure are merely possible examples of implementations, and are set forth only for a clear understanding of the principles of the disclosure. Many variations and modifications may be made to the above-described embodiments of the disclosure without departing substantially from the spirit and principles of the disclosure. All such modifications and variations are intended to be included herein within the scope of this disclosure.
This application claims priority to U.S. provisional application entitled “BIODEGRADABLE IMPLANTS WITH ANTICORROSIVE COATINGS,” having Ser. No. 63/139,890 filed on Jan. 21, 2021, which is entirely incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2022/070120 | 1/10/2022 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63139890 | Jan 2021 | US |
